Niagen Bioscience Share Price Today

Freedom Broker maintains Buy on Niagen, cuts PT to $6

Freedom Broker maintains Buy on Niagen Bioscience. Price target lowered from $8.50 to $6 by Ilya Zubkov. Follows Canaccord Genuity's cut to $7 from $9. Both firms retain Buy ratings despite lower targets.

Niagen Bioscience Q3FY26 Results: Revenue falls 10% to $27.2M, net loss $1.2M

Revenue declined 10% YoY to $27.2 million in Q3FY26, driven by distribution timing and competitive pressures. Net loss of $1.2 million ($0.01/share) compared to net income of $0.06/share in the prior year. Cash position strengthened to $69.5 million with no debt, maintaining positive operating cash flow of $2.6 million. Gross margin contracted 160 bps to 62.9% due to product mix changes. Pharmaceutical asset NB4168 IND-enabling studies targeted for completion in early 2027.

Niagen Bioscience launches NanoCloud to expand into skincare market

Launched Niagen NanoCloud as the first product in the permanent Tru Niagen Skincare category. Utilizes waterless sachet technology to prevent NAD+ degradation found in traditional serums. Limited release achieved 4.8-star average rating with 97% positive reviews. 49% of early adopters were existing oral Tru Niagen customers, indicating strong cross-sell potential. Targets global skincare market projected to reach $227.13 billion by 2034.

Niagen Bioscience Q3FY26 Results: Earnings call set for Nov 4

Niagen Bioscience to report Q3FY26 results on November 4, 2026. Conference call scheduled for 4:30 p.m. ET after market close. Webcast and press release available via Investor Relations website.

Niagen Bioscience Q2FY26 Results: Revenue $29.8M, net income falls to $1M

Revenue reached $29.8 million, with Tru Niagen sales up 6% YoY to $24.2 million. Net income fell to $1 million ($0.01 EPS) from $0.05 EPS in Q2 2025. E-commerce revenue grew 14% to $20.5 million, driving consumer segment performance. Selling and marketing expenses increased to 34% of net sales from 26.4% YoY. Cash position stands at $66.7 million with no debt, supporting strategic investments.

Niagen Bioscience cites study linking CD38 to placental NAD+ decline

Independent study in Nature Communications identifies CD38 enzyme as primary driver of NAD+ decline in aging placental tissue. Research across human, mouse, and pig models shows older mothers have lower placental NAD+, NADH, and NADP+ levels. Oral nicotinamide riboside (NR) or CD38 inhibition restored NAD+ and improved fetal growth in aged pregnant mice. Niagen Bioscience states it did not conduct, fund, or design the study and its proprietary ingredient was not used.